The Human Immune Monitoring Center (HIMC) Shared Resource provides state-of-the-art assays that measure biomarkers relevant to the immune system or specific pathogens. Examples of biomarkers that are specifically relevant to cancer include changes in lymphocyte signaling pathways, serum cytokines, and specific immune responses that target tumor cells. This resource offers Cancer Center members specialized assays that monitor the effects and efficacy of immunotherapies and vaccination strategies that are becoming increasingly important alternatives or adjuvants to conventional forms of cancer treatment. In addition, pathogens have been implicated in the etiology of many cancers, and the HIMC offers array methodologies for pathogen identification. The HIMC initiated operations in early 2007, and has attracted many faculty users in the past two years;74% of the current users are Cancer Center members. We expect an increasing demand for our services as new projects and clinical trials in the immune modulation of cancer are developed. Major services provided by the HIMC are Luminex bead-based assays for measuring cytokines, FACS phenotyping and phosphoflow analysis for cell characterization, and the Firefly nanofluidics assay method for detecting phosphorylated proteins. Dr. Holden Maecker is the Facility Director of HIMC and an expert in cancer immunology and immune monitoring. Leadership is provided by Dr. Maecker and oversight is provided by the HIMC Advisory Committee, consisting of 10 faculty and headed by Dr. Mark Davis, who is an internationally known expert in lymphocyte recognition and immune monitoring technologies. He is also the principal inventor of the peptide-MHC tetramer technology to monitor specific T cell responses. Future goals of the HIMC are to introduce for general use the multiplex peptide-MHC tetramer technology recently developed by the Davis lab to quantitate and characterize T cell responses to tumor associated antigens and the complementary ELISPOT analysis, which quantitates T and B cell responses. The shared resource will also offer full bioinformatics consulting and data management for its users.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-07
Application #
8475466
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
7
Fiscal Year
2013
Total Cost
$75,786
Indirect Cost
$3
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442
Gee, Marvin H; Han, Arnold; Lofgren, Shane M et al. (2018) Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell 172:549-563.e16
Malta, Tathiane M; Sokolov, Artem; Gentles, Andrew J et al. (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173:338-354.e15
Banerjee, Imon; Gensheimer, Michael Francis; Wood, Douglas J et al. (2018) Probabilistic Prognostic Estimates of Survival in Metastatic Cancer Patients (PPES-Met) Utilizing Free-Text Clinical Narratives. Sci Rep 8:10037
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Rogers, Zoë N; McFarland, Christopher D; Winters, Ian P et al. (2018) Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. Nat Genet 50:483-486
Nair, Viswam S; Sundaram, Vandana; Desai, Manisha et al. (2018) Accuracy of Models to Identify Lung Nodule Cancer Risk in the National Lung Screening Trial. Am J Respir Crit Care Med 197:1220-1223
She, Richard; Jarosz, Daniel F (2018) Mapping Causal Variants with Single-Nucleotide Resolution Reveals Biochemical Drivers of Phenotypic Change. Cell 172:478-490.e15

Showing the most recent 10 out of 322 publications